Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2024 02:00 ET | Source: Essential Pharma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
January 08, 2024 02:00 ET | Source: Essential Pharma

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...
June 21, 2023 02:00 ET | Source: Essential Pharma

Essential Pharma appoints Lee Morley as Non-Executive Director to the Board

Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on...
May 24, 2023 02:00 ET | Source: Essential Pharma

Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer

Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Zug, Switzerland & Egham, UK – 24 May 2023 – Essential Pharma, an international specialty pharma company...
January 19, 2023 02:00 ET | Source: Essential Pharma

Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential Pharma en adéquation avec les besoins médicaux et la stratégie d'expansion de l'entreprise

Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential Pharma en adéquation avec les besoins médicaux et la stratégie d'expansion de l'entreprise Une...
December 15, 2022 07:06 ET | Source: Essential Pharma

UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product

UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need...
December 07, 2022 02:00 ET | Source: Essential Pharma

Essential Pharma Announces the Acquisition of HALDOL®

Essential Pharma Announces the Acquisition of HALDOL® HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition...